SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Elon Musks warning that tighter debt markets could trigger failures and consolidation among AI neoclouds has fueled concern about Nebiuss capital-intensive expansion and weighed on sentiment. Bulls counter that Nebius has secured financing and customer commitments, arguing it is better positioned than weaker sector peers; others remain concerned about debt access and execution risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Elon Musks warning that many neocloud operators could fail or consolidate, alongside concerns about debt-heavy AI data-center expansion and tighter financing, is driving attention to IREN and its peers. Traders debate whether the comments amplify genuine funding and execution risks or are self-interested criticism, with bulls pointing to IRENs contracts and infrastructure while bears warn of further losses.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas positive Phase 3 melanoma-vaccine results with Mercks Keytruda have driven discussion, but shares sold off as traders judged the data against heightened expectations and questioned the treatments commercial potential. Bulls view the results as validation for a broader cancer-vaccine platform, while skeptics point to approval, adoption and profitability uncertainties and await evidence in other cancers.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazils presidential election has driven sharp swings in Brazilian stocks, including NU, as traders react to political and economic uncertainty. The community is split between viewing the selloff as a buying opportunity and waiting for the stock to stabilize, with some arguing the companys fundamentals remain strong.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs event-driven Phase 3 REGAL trial of its GPS leukemia vaccine dominates discussion, with traders focused on the final analysis triggered at 80 survival events and anticipating a possible data update around ASH. Bulls speculate the prolonged wait could reflect a survival benefit, while skeptics question the delay, the companys quiet period, and whether the blinded trial will ultimately succeed; SLS009 updates are a secondary catalyst.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas election victory after markets had positioned for a Bolsonaro win prompted a sharp selloff in Brazilian shares, including Petrobras. Traders are divided between concerns about political and dividend risks under Lula and the view that the decline is an overreaction given Petrobras oil business and valuation.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is drawing attention after Brazils unexpected Lula victory triggered a sharp selloff, as traders worry about political and economic uncertainty and the markets apparent positioning for a Bolsonaro win. Many are bearish on Brazils outlook, while others argue the decline is an overreaction and see a potential buying opportunity.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

Traders link XPs sharp move to Brazils first-round election results, which they view as improving sentiment toward Brazilian equities after a stronger-than-expected showing by Bolsonaro-aligned candidates. Some see the rally as a bullish political catalyst, while skeptics argue it is speculative and could reverse.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCelleras ABCL635 clinical results for menopausal hot flashesand its presentation of additional Phase 1/2 safety and patient-reported dataare the dominant focus, alongside anticipation for further durability data. The reaction is largely bullish on the program and its potential, while some traders caution that expectations may be high and the stock could consolidate or sell off without stronger new evidence.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

Biotech is pulling back after a recent sector rally, with traders debating whether the weakness is a pause or a broader deterioration. IBBs hold near its 50-day moving average is cited as support, while some see large-cap biotech holding up better than smaller names.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models

Equity

The firm believes the new lineup could significantly expand Rivian's addressable EV market.

Tesla’s Robotaxi Push Drives Stifel’s 25% Upside Call 

Stifel cited strong third-quarter results and promising advances in autonomous driving as drivers for the price target boost.

XPeng Gets A Price Target Hike From Morgan Stanley, Retail Wonders What Happened To Short Sellers

The new price of $28 target implies a 37% upside to the stock’s closing price on Wednesday. 


XPeng Launches MONA M03 Max With ADAS In $20,000 Price Segment, But Retail’s Not Super Excited

The vehicle also features a smart cockpit with features that outperform those of higher-priced vehicles, as well as the previously launched MONA M03 variant, the company said.

XPeng Stock Gets Price Target Hikes From Macquarie, Bernstein, BofA After Upbeat Q1: Retail’s Cautiously Optimistic

As per Macquarie analyst Eugene Hsiao, XPeng continues to execute ahead of expectations in a difficult domestic EV market.

XPeng Stock Rises Pre-Market On Upbeat Q1 Earnings, Strong Q2 Forecast: Retail Turns Bullish

For the second quarter, XPeng expects to deliver between 102,000 and 108,000 vehicles, representing a YoY increase of as much as 257.5%.

XPeng Forecasts Q1 Revenue To More Than Double But Stock Slides After Massive Gains In 2025: Retail Goes Extreme Bullish

XPeng expects its total revenue for the first quarter of 2025 to be between RMB 15 billion and RMB 15.7 billion, marking a year-on-year jump of up to 140% on the back of strong delivery numbers.

VanEck ETF Trust - VanEck Low Carbon Energy ETF

Neutral Sentiment

<ul class="summary-bullets"><li>TD Cowen raised its price target on Rivian shares to $20 from $17.</li><li>The firm estimates that annual sales for R2 could eventually range from roughly 212,000 to 335,000 vehicles.</li><li>Rivian plans to price the R2 SUV at roughly $45,000 with roll-out beginning in the second-quarter.&nbsp;</li></ul>Rivian Automotive Inc. (RIVN) received a vote of confidence from TD Cowen, which upgraded the electric vehicle maker’s stock to a ‘Buy’ rating from ‘Hold’ while lifting its price target.&nbsp;TD Cowen raised its price target on Rivian shares to $20 from $17, according to TheFly.&nbsp;<h2 class="st-heading-2">R2 Growth Potential</h2>The revised outlook comes as the firm evaluated potential demand for Rivian’s upcoming R2 vehicle platform, which could significantly expand the company’s market reach.TD Cowen’s analysts estimate that demand for R2 could eventually range from roughly 212,000 to 335,000 vehicles. They noted that this projection may exceed current Wall Street expectations for 2027.&nbsp;Following the upgrade,&nbsp;<a href="https://stocktwits.com/symbol/RIVN">Rivian Automotive stock</a> traded over 4% higher in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘low’ message volume levels.&nbsp;<h2 class="st-heading-2">The Affordable R2 Lineup&nbsp;</h2>The next-generation EVs are expected to target a broader, more affordable segment of the EV market than Rivian’s current R1 lineup. By expanding into a larger customer base, Rivian aims to ramp up production and improve long-term revenue growth.Rivian plans to price the R2 SUV at roughly $45,000, cheaper than the R1 models that start around $70,000. The R2 roll-out will begin in the second-quarter (Q2).&nbsp;In its fourth-quarter (Q4) earnings call, Rivian CFO Claire McDonough noted that the operational complexity tied to the R2 rollout could put pressure on automotive gross profit in Q2 and the third quarter of 2026, even though total gross profit is expected to rise compared with the previous year.RIVN stock has gained over 57% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-ceo-jensen-huang-frames-ai-as-foundational-infrastructure-ahead-of-gtc-event-next-week/cZdotbFRI7J">Nvidia CEO Jensen Huang Frames AI As ‘Foundational Infrastructure’ Ahead Of GTC Event Next Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Rivian logo is on display during the 2025 Los Angeles Auto Show at the Los Angeles Convention Center on November 23, 2025 in Los Angeles, California

Rivian Automotive Inc. (RIVN) received a vote of confidence from TD Cowen, which upgraded the electric vehicle maker’s stock to a ‘Buy’ rating from ‘Hold’ while lifting its price target. 

ALPS Fund Services - ALPS Clean Energy ETF

CRISPR Therapeutics AG

iShares Self-Driving EV and Tech ETF

Krane Shares Trust - KraneShares Electric Vehicles and Future Mobility Index ETF

VanEck Low Carbon Energy ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$129.40
Prev Close	$130.51
Open	$129.25
Dividend Yield	N/A
50-Day Moving Average	$136.49
Beta	N/A
Avg. Volume	872.23
PE Ratio	N/A

52-Week High	$157.27
52-Week Low	$125.23
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

SMOG Fundamentals